Kilitch Drugs (India) Limited Announces 1:1 Bonus Share Allotment

1 min read     Updated on 25 Mar 2026, 06:07 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Kilitch Drugs (India) Limited's board approved allotment of 1,74,80,782 bonus equity shares in 1:1 ratio on March 25, 2026, with record date set as March 24, 2026. The bonus issue doubles the company's paid-up share capital from Rs. 17.48 crore to Rs. 34.96 crore, with new shares ranking pari-passu with existing equity shares.

powered bylight_fuzz_icon
35987866

*this image is generated using AI for illustrative purposes only.

Kilitch Drugs (India) Limited has announced a significant corporate action with its Board of Directors approving a bonus share allotment in a 1:1 ratio. The decision was taken during the board meeting held on March 25, 2026, marking a major milestone for the pharmaceutical company's shareholders.

Bonus Share Allotment Details

The company has approved the allotment of 1,74,80,782 bonus equity shares of Rs. 10 each to its shareholders. Under the 1:1 ratio scheme, shareholders will receive one bonus equity share of Rs. 10 each for every one equity share of Rs. 10 each currently held. The record date for determining eligible shareholders has been fixed as March 24, 2026.

The bonus equity shares will rank pari-passu in all respects with the existing fully paid-up equity shares of the company, ensuring equal rights and benefits for all shareholders.

Impact on Share Capital Structure

The bonus issue has resulted in a significant expansion of the company's equity base:

Particulars No. of Shares Face Value (per share in Rs.) Amount (in Rs.)
Paid-up Share Capital (Pre-Bonus Issue) 17480782 10 174807820
Paid-up Share Capital (Post Bonus Issue) 34961564 10 349615640

The paid-up equity share capital has effectively doubled from Rs. 17.48 crore to Rs. 34.96 crore following the bonus share allotment.

Board Meeting Proceedings

The board meeting commenced at 10:30 hours and concluded at 12:05 hours on March 25, 2026. The decision was communicated to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The announcement was signed by Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, bearing DIN: 00147876. This bonus share allotment represents the company's commitment to rewarding its shareholders while strengthening its equity structure for future growth initiatives.

How might this bonus share issuance affect Kilitch Drugs' stock liquidity and trading volumes in the coming quarters?

What strategic growth initiatives or expansion plans could Kilitch Drugs be preparing for with this strengthened equity structure?

Will the doubled share capital impact the company's dividend policy and payout ratios for future distributions?

Kilitch Drugs Sets March 24 Record Date for 1:1 Bonus Share Issue

2 min read     Updated on 17 Mar 2026, 03:36 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Kilitch Drugs has announced March 24, 2026 as the record date for its 1:1 bonus share issue, following overwhelming shareholder approval during the March 13 EGM. The bonus shares will be deemed allotted on March 25, 2026, with eligible shareholders receiving one additional ₹10 equity share for every existing share held.

powered bylight_fuzz_icon
34949266

*this image is generated using AI for illustrative purposes only.

Kilitch drugs (India) Limited successfully conducted its Extra-Ordinary General Meeting on March 13, 2026, addressing significant corporate restructuring initiatives through video conferencing. Following overwhelming shareholder approval for bonus share issuance, the pharmaceutical company has now announced the record date for determining eligible shareholders.

Record Date and Allotment Timeline

The company has officially fixed March 24, 2026 as the record date for determining shareholders entitled to receive bonus equity shares in the ratio of 1:1. This announcement was made through a regulatory filing to BSE Limited and National Stock Exchange of India Limited under Regulation 42 of SEBI regulations.

Parameter: Details
Record Date: March 24, 2026 (Tuesday)
Deemed Allotment Date: March 25, 2026 (Wednesday)
Bonus Ratio: 1:1 (One bonus share for every existing share)
Share Face Value: ₹10 per equity share

Eligibility Criteria for Bonus Shares

Shareholders whose names appear on the company's register of members for physical shares and on the register of beneficial owners maintained by depositories for electronic shares as of closing hours on March 24, 2026 will be entitled to receive the bonus equity shares. The bonus issue offers existing shareholders one additional equity share of ₹10 each for every share held.

EGM Resolutions and Voting Results

The bonus share proposal was approved during the Extra-Ordinary General Meeting held on March 13, 2026, from 11:30 am to 11:42 am through video conferencing. Both major resolutions presented to shareholders received overwhelming support.

Resolution: Description Votes in Favor Votes Against Result
Resolution No. 1: Increase authorized capital and amend Capital Clause of Memorandum of Association 12,396,194 (100.00%) 1 (0.00%) Passed
Resolution No. 2: Approve issue and allotment of bonus shares in 1:1 ratio 12,396,194 (100.00%) 1 (0.00%) Passed

Shareholder Participation and Compliance

The EGM witnessed participation from 48 members, including 3 promoter group members and 45 public shareholders. The meeting was chaired by Mr. Mukund Mehta, Managing Director, with comprehensive participation from the leadership team including Mrs. Mira Mehta, Mr. Bhavin Mehta, and three Independent Directors.

Voting Details: Information
Total Shares Outstanding: 17,480,782
Total Votes Polled: 12,396,195 (70.91%)
Promoter Participation: 100.00%
Public Institution Participation: 66.67%

The record date announcement, signed by Managing Director Mukund Mehta, ensures full compliance with regulatory requirements and marks the completion of the bonus share issuance process that will strengthen the company's capital structure while rewarding existing shareholders.

More News on Kilitch Drugs